I seminari dipartimentali si svolgeranno secondo il seguente calendario, due volte al mese, dalle 13:00 alle 13:40 in aula seminari al II piano di largo Donegani 2 (ex Wild), a Novara.
Aggiungi gli eventi al tuo calendario cliccando qui https://goo.gl/jtddhG
1) Pharmacogenetics and genetics of migraine: our contribution to the field
03 ottobre 2018; Sarah Cargnin (UNIUPO - DSF)
Episodic migraine is a disabling neurovascular disease that affects around 10% of the worldwide adult population. Despite triptans are now considered as the gold-standard acute treatment for migraine, their use is limited by at least two main drawbacks: first, a consistent proportion of migraineurs do not benefit from these medications; second, it has been shown that the overuse of triptans per se is, paradoxically, one of the major causes of migraine chronification into Medication Overuse Headache (MOH). In the last years we conducted several studies aimed at identifying single neuclotide polymorphisms as genetic predictors of the clinical response to triptans or of the risk of developing MOH. We herein propose the use of a polygenic risk score approach as an adequate tool to unravel the genetic/pharmacogenetic basis of migraine and its chronification.
2) Role of the epigenetic modulators KDM6B and EZH2 in malignant mesothelioma
17 ottobre 2018; Giulia Pinton (UNIUPO – DSF)
Mesothelioma is a type of cancer that forms on the thin protective lining that cover the lungs and other internal organs, often associated with exposure to asbestos. For patients with relapsed or refractory mesothelioma, there are currently no approved treatment options.
Tazemetostat, a first-in-class EZH2 (Enhancer of Zeste homology 2) inhibitor, is currently being studied as a monotherapy in ongoing Phase 1 and 2 programs. EZH2 is a methyltransferase that trimethylates histone H3 lysine 27 (H3K27me3) on chromatin. This repressive mark is removed by the lysine demethylase KDM6B. We assessed the role of EZH2 and KDM6B in mesothelioma derived cells, cultured as monolayer or as spheroids.
3) From mass spectrometry to biochemistry: in vitro and in vivo applications
07 novembre 2018; Marcello Manfredi (UNIUPO – IRCAD)
4) MORPHEUS: an automated tool for unbiased and reproducible cell morphometry
21 novembre 2018; Federico Ruffinatti (UNIUPO – DSF)
5) Relazioni struttura-attività del diterpene antitumorale EBC-46
05 dicembre 2018; Giovanni Battista Appendino (UNIUPO – DSF)
6) Nucleotide Excision Repair and direct DNA damage reversal in Mycobacterium tuberculosis: a biochemical and structural perspective
19 dicembre 2018; Riccardo Miggiano (UNIUPO – DSF)
7) Real World Evidence: quanto è davvero reale?
09 gennaio 2019; Francesco Barone Adesi (UNIUPO – DSF)
8) A new possibility on acute myelogenous leukemia (AML): targeting myeloid differentiation using potent and innovative human dihydroorotate dehydrogenase (hDHODH) inhibitors
23 gennaio 2019; Marco Lolli (UNITO)
9) Lipotoxicity-mediated disruption of adult hypothalamic neural progenitor cells as a potential contributor in Metabolic Syndrome
06 febbraio 2019; Heather Bondi (UNIUPO – DSF)
10) Regulation of neuronal protein expression and function by astroglial calcineurin
20 febbraio 2019; Laura Tapella (UNIUPO – DSF)